DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 211 filers reported holding DENALI THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 4.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $0 | – | 0 | – | 0.00% | – |
Q2 2023 | $0 | – | 0 | – | 0.00% | – |
Q1 2023 | $0 | – | 0 | – | 0.00% | – |
Q4 2022 | $0 | – | 0 | – | 0.00% | – |
Q3 2022 | $0 | – | 0 | – | 0.00% | – |
Q2 2022 | $0 | – | 0 | – | 0.00% | – |
Q1 2022 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
Q4 2021 | $464,000 | – | 10,402 | – | 0.00% | – |
Q3 2021 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
Q2 2021 | $566,000 | +37.4% | 7,210 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $412,000 | – | 7,210 | – | 0.00% | – |
Q4 2020 | $0 | – | 0 | – | 0.00% | – |
Q3 2020 | $0 | – | 0 | – | 0.00% | – |
Q2 2020 | $0 | – | 0 | – | 0.00% | – |
Q1 2020 | $0 | – | 0 | – | 0.00% | – |
Q4 2019 | $0 | – | 0 | – | 0.00% | – |
Q3 2019 | $0 | – | 0 | – | 0.00% | – |
Q2 2019 | $0 | – | 0 | – | 0.00% | – |
Q1 2019 | $0 | – | 0 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |